Truist Securities Maintains Buy on Astrana Health, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Jailendra Singh maintains a Buy rating on Astrana Health (NASDAQ:ASTH) and raises the price target from $50 to $59.
August 09, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Jailendra Singh maintains a Buy rating on Astrana Health and raises the price target from $50 to $59.
The raised price target and maintained Buy rating from a reputable analyst at Truist Securities is likely to positively impact investor sentiment and drive short-term price appreciation for Astrana Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100